Dementia

>

Latest News

Eisai Files sBLA for Lecanemab-irmb Maintenance Dose, Reports Delay on SC Formulation / image credit Alzheimer disease concept: ©Zerbor/stock.adobe.com
Eisai Files sBLA for Lecanemab-irmb Maintenance Dosing, Reports Delay on SC Formulation

April 1st 2024

The sBLA for once-monthly maintenance IV dosing of lecanemab is complete but a rolling application for a weekly subQ option has been set back, said Eisai.

Eli Lilly has announced that the US Food and Drug Administration's (FDA)  Peripheral and Central Nervous System Drugs Committee will convene for a meeting to deliberate over its antiamyloid therapy donanemab, and the supportive phase 3 TRAILBLAZER-ALZ 2 trial (NCT04437511).1 The date of the advisory meeting has yet to be set by the FDA, and, as a result, the timing of expected FDA action for the treatment will be delayed beyond the first quarter of 2024.1
Lilly Investigational Alzheimer Agent Donanemab Phase 3 Findings Under FDA Review

March 8th 2024

/ image credit Amyloid plaque: ©Artur/stock.adobe.com
Plasma Immunoassay for Alzheimer Disease Found Highly Accurate and is Commercially Available

February 29th 2024

Tighter Glycemic Control in T2D Reduces Risk for All-Cause Dementia: Daily Dose / image credit: ©New Africa/AdobeStock
Tighter Glycemic Control in T2D Reduces Risk for All-Cause Dementia: Daily Dose

February 21st 2024

Tighter Glycemic Control in Type 2 Diabetes May Reduce Risk for All-Cause Dementia: New Findings / image credit blood glucose: ©Sophia Winters/stock.adobe.com
Tighter Glycemic Control in Type 2 Diabetes May Reduce Risk for All-Cause Dementia: New Findings

February 14th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.